HC Wainwright set a $3.00 target price on Lipocine (NASDAQ:LPCN) in a research note issued to investors on Friday, January 12th, Marketbeat Ratings reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other equities analysts also recently commented on LPCN. Canaccord Genuity reiterated a hold rating and issued a $2.00 target price (down from $11.00) on shares of Lipocine in a report on Tuesday, January 9th. Ladenburg Thalmann Financial Services restated a buy rating and set a $11.00 price objective on shares of Lipocine in a report on Thursday, January 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $13.50.
Shares of Lipocine (NASDAQ:LPCN) opened at $1.36 on Friday. Lipocine has a one year low of $1.30 and a one year high of $5.33. The stock has a market cap of $28.83, a price-to-earnings ratio of -1.43 and a beta of 1.93.
Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.05. analysts anticipate that Lipocine will post -1.04 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Lipocine by 39.7% in the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after purchasing an additional 155,110 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Lipocine by 18.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after purchasing an additional 24,000 shares in the last quarter. P.A.W. Capital Corp purchased a new stake in Lipocine in the 3rd quarter worth approximately $397,000. Federated Investors Inc. PA boosted its position in Lipocine by 9.2% in the 2nd quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after purchasing an additional 7,429 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in Lipocine in the 2nd quarter worth approximately $300,000. Institutional investors and hedge funds own 22.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/21/lipocine-lpcn-given-a-3-00-price-target-by-hc-wainwright-analysts.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.